Kisspeptin has meaningful human research in reproductive and endocrine science. Much of that work is experimental or specialist, and it does not make kisspeptin a generally approved fertility or sexual-function treatment.
Still uncertain: Routine fertility or sexual-function benefit and long-term safety outside trials are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Reproductive neuropeptide
Entity type
Peptide
Research focus
Reproductive endocrinology, fertility, psychosexual research
Human evidence
Controlled human studies demonstrate reproductive-hormone effects, oocyte-maturation triggering in specialist IVF settings, and acute sexual/emotional brain-processing effects in small randomized HSDD studies in men and women. Long-term HSDD efficacy is not established.
Regulatory status
No general FDA-approved kisspeptin therapy identified.
Main limitations
Routine fertility/sexual-function efficacy and long-term safety outside trials are not established.
Safety
Acute research exposure appears tolerable in small studies, but therapeutic long-term safety is not established; FDA highlights limited safety information for compounded kisspeptin-10.
Evidence reviewed
2026-09-18
i
Controlled human studies demonstrate reproductive-hormone effects, oocyte-maturation triggering in specialist IVF settings, and acute sexual/emotional brain-processing effects in small randomized HSDD studies in men and women. Long-term HSDD efficacy is not established.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Acute research exposure appears tolerable in small studies, but therapeutic long-term safety is not established; FDA highlights limited safety information for compounded kisspeptin-10.
Short experimental studies report generally acceptable acute tolerability, but long-term safety for repeated lifestyle use is not established. Fertility use requires specialist monitoring because of potent reproductive-axis effects.
Route / formulation boundaryEvidence differs between kisspeptin-10 and kisspeptin-54 and between IV and other routes.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human reproductive-study regimen; Published IVF trigger research regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
